Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

LIFEVALVE

financed

Closed

Living autologous heart valves for minimally invasive implantable procedures

Cardiovascular disease still represents the Killer No.1 in the EU accounting for substantial morbidity/mortality and health care cost. Heart valve replacement represents the most common surgical therapy for valvular heart disease... see more

30/04/2015

UZH

16M€

Project Budget: 16M€

Project leader

University of Zurich No se ha especificado una descripción o un objeto social para esta compañía.

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 6 Participantes

Financing granted El organismo FP7 notifico la concesión del proyecto The day 2015-04-30 We do not have the information of the call

0% 61% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

UZH

2.47M€ | Leader

DHZB

N.D. | participant

ASML NETHERLANDS B.V.

N.D. | participant

MEDIZINISCHE UNIVERSITAET WI...

N.D. | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project leader

University of Zurich No se ha especificado una descripción o un objeto social para esta compañía.

Project Budget 16M€

participation deadline Sin fecha límite de participación.

Project description Cardiovascular disease still represents the Killer No.1 in the EU accounting for substantial morbidity/mortality and health care cost. Heart valve replacement represents the most common surgical therapy for valvular heart disease with almost 200.000 annual implantations worldwide. Currently, heart valve prosthesis-associated problems occur in 30-35% of patients within 10 years, frequently necessitating risky re-operations. A particularly severe problem relates to children with congenital heart defects (1% of all newborns) who cannot be treated efficiently due to the lack of growths of the clinically available artificial valve prostheses. The principal objective of the LifeValve project is to develop a new therapeutic strategy to treat heart valve disease patients more efficiently. Two novel life science technologies will be combined: tissue engineering and minimally invasive implantation technology. In particular, the scientific and technological approach of the LifeValve project is to develop a clinically relevant tissue engineered living heart valve, with the capacity of regeneration and growths which can be implanted by minimally invasive catheter technology. First clinical trials will be enrolled in paediatric patients addressing the currently unmet dramatic medical need for growing implants. A highly interdisciplinary approach combines basic sciences, medical research, engineering and clinical practice. In addition, close industry-academia collaborations are integrated. It is expected that new knowledge applicable for a much broader field of cardiovascular diseases will be generated by the unique combination of consortium partners each representing opinion leaders in their fields. The consortium is compact comprising all the necessary expertise and skills to realize the precisely planned work in a short period of time.The close collaboration of the well interconnected LifeValve consortium will most efficiently contribute to an added value for the EU.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers